| 书目名称 | Resistance to Targeted Therapies in Multiple Myeloma |
| 编辑 | Silvia CW Ling,Steven Trieu |
| 视频video | |
| 概述 | Develops an understanding of targeted therapies in Multiple Myeloma.Provides a unique review of the mechanism of action and resistance.Features chapters written by internationally-based leaders in the |
| 丛书名称 | Resistance to Targeted Anti-Cancer Therapeutics |
| 图书封面 |  |
| 描述 | .Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors...This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will beuseful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers...This book will provide an insightful knowledge of the biology of |
| 出版日期 | Book 2021 |
| 关键词 | multiple myeloma; targeted therapy; resistance to targeted therapies in multiple myeloma; biology of mu |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-030-73440-4 |
| isbn_softcover | 978-3-030-73442-8 |
| isbn_ebook | 978-3-030-73440-4Series ISSN 2196-5501 Series E-ISSN 2196-551X |
| issn_series | 2196-5501 |
| copyright | Springer Nature Switzerland AG 2021 |
发表于 2025-3-21 19:37:31
